26 Jun 2020
New TMVI therapy to eliminate mitral regurgitation. Evidence and patient selection
Supported by an educational grant from Abbott
Session Coordinator:
N. Dumonteil
Summary
Watch this video if you want to get the latest update on the first commercially available TMVI therapy (Tendyne), to learn about Tendyne clinical experience and how to identify the best candidates for this novel therapy.
Learning Objectives
- To get the latest update on the first commercially available TMVI therapy (Tendyne)
- To learn about Tendyne clinical experience and how to identify the best candidates for this novel therapy